Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Features
    • How-to
    • Knowledge & Insights
    • Guest Contributions
  • Partners
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Scaling-up in Europe
    • Blue Tulip Awards
    • Partner with us
    • Promoted content
  • Jobs
  • About us
    • Partner with us
    • About
    • Team
    • Newsletter
  • Contact
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Features
    • How-to
    • Knowledge & Insights
    • Guest Contributions
  • Partners
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Scaling-up in Europe
    • Blue Tulip Awards
    • Partner with us
    • Promoted content
  • Jobs
  • About us
    • Partner with us
    • About
    • Team
    • Newsletter
  • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

Berlin’s Dopavision raises €12M to halt myopia progression in children and adolescents; here’s how

Vishal Singh by Vishal Singh
July 19, 2021
in (Crowd)funding, News
Dopavision

Image credit: Dopavision

48
SHARES
LinkedInTwitterWhatsAppFacebook

Dopavision is a Berlin-based company developing digital therapeutics for myopia. Nearsightedness (myopia) is a vision condition in which patients can see objects near to them clearly, but objects farther away are blurry.

Dopavision raises Series A round

In a recent development, the company announced that it has raised €12M in its Series A round of funding. The round was led by Seventure Partners and was joined by Novartis Pharmaceuticals.

- Partner content -
EIT Digital
EIT Digital Challenge 2022 is here!
Calling all European deep-tech scaleups for EIT Digital Challenge 2022Show More
Calling all European deep-tech scaleups for EIT Digital Challenge 2022 Show Less
Read more

In addition, Dopavision’s existing investors such as Boehringer Ingelheim Venture Fund and Ababax Health also invested in this round.

The company has raised total funding of €14.7M in private equity and public grants and is supported by the German government via the “Industrie-in-Klinik” program of the German Federal Ministry of Education and Research BMBF.

Myopia – a global public health concern

According to the company, Myopia is recognised as a public health concern around the world as it causes visual impairment, and is expected to reach a global prevalence of 50 per cent by 2050. Its condition manifests blurring of digital objects due to image focusing in front of the retina instead of falling on the retina, most often caused by excessive elongation of the eyeball during growth. 

Dopavision’s goal is to develop a clinically validated therapy to halt myopia progression in children and adolescents.

What does Dopavision offer?

Founded in 2017 by Hamed Bahmani and Stefan Zundel, Dopavision helps control myopia by providing transformative treatments and addressing the disease at an early stage, providing medical benefits for later years of life.

With its lead product, MyopiaX, the company is developing a therapeutic for childhood myopia that can be invisibly integrated into the use of a smartphone.

According to co-founder Dr. Hamed Bahmani, “The extensive use of smartphones is suspected to worsen childhood myopia but stopping children from using them is unrealistic. Therefore, we have decided to transform the use of digital devices into a beneficial therapeutic activity. Our first-of-its-kind MyopiaX combines ease of use with an exciting user experience that promotes adherence to the therapy with the goal of addressing this serious medical condition already at a young age.”

Technology to fix Myopia

According to a statement, Dopavision targets children and young adolescents, leveraging a light-based technology that stimulates specific photosensitive cells of the retina, which in turn modulate retinal dopamine, a key neurotransmitter involved in eye growth.

Dopavision claims that its product, MyopiaX, has the potential to become the first digital therapy to control childhood myopia. It is designed to achieve a medical effect while children play exciting games or use educational digital content and can be conveniently integrated into their daily routine. It runs on standard digital devices and is easy to use for children under minimal supervision of their parents.

How will the funds be utilised?

The raised capital from this round will help Dopavision to fund the clinical development of MyopiaX. In addition, the company is also planning to demonstrate its safety and efficacy in clinical studies and advance this treatment to market.

Moreover, the funding will also help Dopavision to further develop its product activities in order to provide digital treatments for children leveraging games, educational or cognitive training applications. The company also intends to use this capital to continue recruitment.

 - Partner content -
How cybersecurity scaleup Intigriti conquered the world?
How cybersecurity scaleup Intigriti conquered the world?
Catch our interview with Paul Down, Head of Sales at Intigriti.
Catch our interview with Paul Down, Head of Sales at Intigriti. Show Less
Read more
Tags: featuredfundingnews
Share3Tweet12SendShare19

Partner content | Work with us

Tokenisation is the future of the financial services industry, and Luxembourg’s Tokeny is at the helm of this change

Copilot for growers: Source.ag’s Rien Kamman explains how it helps growers increase their fresh produce with AI

Waste problem is complex, but Seenons has a solution: CEO and co-founder Joost Kamermans explains the plan

Want to scale your business in Germany and Europe? Here’s how the Scaleup Landing Pad Hamburg can help

Is your deep tech scaleup aiming high? The EIT Digital Challenge 2022 can get you there

Silicon Canals | Jobs


Breaking news from Amsterdam | Partner

Amsterdam and Paris-based Trezy bags €1M, opens European headquarters in the Dutch capital

Amsterdam’s Just Eat Takeaway made progress towards profitability in H1 2022: Report

9 Amsterdam-based startups that are cooling the planet

Amsterdam-based CarbonCancel, a company that helped offset carbon footprint, shuts shop: Know more

Advertisement

  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy Policy
  • Cookie Policy (UK)
  • Cookie Policy (EU)
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2022 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Features
    • How-to
    • Knowledge & Insights
    • Guest Contributions
  • Partners
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Scaling-up in Europe
    • Blue Tulip Awards
    • Partner with us
    • Promoted content
  • Jobs
  • About us
    • Partner with us
    • About
    • Team
    • Newsletter
  • Contact

Silicon Canals 2014-2022 | Website: Bright Idiots

Stay updated with the Silicon Canals daily and weekly newsletters.
We promise we won't spam you. You can choose to unsubscribe anytime.
Stay updated with the Silicon Canals daily and weekly newsletters.
We promise we won't spam you. You can choose to unsubscribe anytime.
Silicon Canals
Manage your privacy

To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Statistics

Marketing

Features
Always active

Always active
Manage options Manage services Manage vendors Read more about these purposes
Manage options
{title} {title} {title}
X
X